Back
 CM  Vol.6 No.3 , September 2015
Retinal Functional Changes Measured by Microperimetry after Intravitreal Ranibizumab Injection and Sulfotanshinone Sodium Injection for Macular Edema Secondary to Retinal Vein Occlusion
Abstract: Objectives: To study the visual field changes after intravitreal ranibizumab (IVR) injection and sulfotanshinone sodium (SS) injection for macular edema (ME) secondary to retinal vein occlusion (RVO), and discuss the value of microperimetry as a routine diagnostic test in the follow-up of RVO patients. Methods: This was a retrospective, interventional, case-series study. Twelve eyes of 12 RVO patients, including 6 eyes with central RVO (CRVO) and 6 eyes with branch RVO (BRVO) were included. The eyes were treated with IVR (0.5 mg) injections and SS injections (20 mg per day, one week consecutively in one month). The outcomes measured included best corrected visual acuity (BCVA), central retinal thickness (CRT), mean defect (MD), pattern standard deviation (PSD), macular light sensitivity of the central 16 points in CRVO group and the central 8 points in BRVO group before and after the treatment. Statistical analyses were then performed on the main outcome measures. Results: An improvement of BCVA was found in all patients after treatment with significant difference (t = 7.74, p < 0.01). CRT improved from (700.3 ± 184.9) μm before treatment to (235.3 ± 36.5 μm) after treatment (t = 8.24, p < 0.01). As for the results of visual field, MD improved significantly (t = 5.83, p < 0.01), whereas the changes of PSD showed no significant importance (t = 2.17, p > 0.05). All RVO patients had their macular light sensitivity of the involved part improved significantly (t = 5.03, p < 0.01). Both the macular light sensitivity of the central 16 points in the CRVO group and the macular light sensitivity of the central 8 points in the BRVO group improved with statistical importance (t = 3.78, p < 0.05; t = 5.38, p < 0.01). The Pearson’s correlation was calculated among BCVA, MD, macular light sensitivity and CRT. No obvious significance was found between CRT and BCVA outcomes, whereas MD and mean macular light sensitivity outcomes were closely related to BCVA results in the BRVO group and the latter showed a more intimate correlation. No similar correlation was found in RVO and CRVO group. Conclusion: IVR injection and SS injection together could effectively improve the therapeutic effect in RVO patients with ME. Microperimetry could be used as a routine diagnostic test and a possible valuable tool in the follow-up of patients with RVO, especially in BRVO.
Cite this paper: Lu, B. and Wu, X. (2015) Retinal Functional Changes Measured by Microperimetry after Intravitreal Ranibizumab Injection and Sulfotanshinone Sodium Injection for Macular Edema Secondary to Retinal Vein Occlusion. Chinese Medicine, 6, 181-186. doi: 10.4236/cm.2015.63020.
References

[1]   Querques, G., Triolo, G., Casalino, G., García-Arumí, J., Badal, J., Zapata, M., Boixadera, A., Castillo, V.M. and Bandello, F. (2013) Retinal Venous Occlusions: Diagnosis and Choice of Treatments. Ophthalmic Research, 49, 215-222.
http://dx.doi.org/10.1159/000346734

[2]   Hahn, P. and Fekrat, S. (2012) Best Practices for Treatment of Retinal Vein Occlusion. Current Opinion in Ophthalmology, 23, 175-181.
http://dx.doi.org/10.1097/ICU.0b013e3283524148

[3]   Rogers, S., McIntosh, R.L., Cheung, N., Lim, L., Wang, J.J., Mitchell, P., et al. (2010) The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology, 117, 313-319.
http://dx.doi.org/10.1016/j.ophtha.2009.07.017

[4]   Gregori, N.Z., Rosenfeld, P.J., Puliafito, C.A., Flynn Jr., H.W., Lee, J.E., Mavrofrides, E.C., et al. (2006) One-Year Safety and Efficacy of Intravitreal Triamcinolone Acetonide for the Management of Macular Edema Secondary to Central Vein Occlusion. Retina, 26, 889-895.
http://dx.doi.org/10.1097/01.iae.0000237111.82357.30

[5]   Prager, F., Michels, S., Kriechbaum, K., Georgopoulos, M., Funk, M., Geitzenauer, W., et al. (2009) Intravitreal Bevacizumab (Avastin®) for Macular Oedema Secondary to Retinal Vein Occlusion: 12-Month Results of Prospective Clinical Trial. British Journal of Ophthalmology, 93, 452-456.
http://dx.doi.org/10.1136/bjo.2008.141085

[6]   Brown, D.M., Campochiaro, P.A., Bhisitkul, R.B., Ho, A.C., Gray, S., Saroj, N., et al. (2011) Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study. Ophthalmology, 118, 1594-1602.
http://dx.doi.org/10.1016/j.ophtha.2011.02.022

[7]   Lu, B.W. and Wu, X.W. (2015) Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion. Chinese Medicine, 6, 83-89.
http://dx.doi.org/10.4236/cm.2015.62009

[8]   Rohrschneider, K., Bueltmann, S. and Springer, C. (2008) Use of Fundus Perimetry (Microperimetry) to Quantify Macular Sensitivity. Progress in Retinal and Eye Research, 27, 536-548.
http://dx.doi.org/10.1016/j.preteyeres.2008.07.003

[9]   Winterhalter, S., Lux, A., Maier, A.K., Scholz, C., Heußen, F.M.A., Huber, K.K. and Joussen, A.M. (2012) Microperimetry as a Routine Diagnostic Test in the Follow-Up of Retinal Vein Occlusion? Graefe’s Archive for Clinical and Experimental Ophthalmology, 250, 175-183.
http://dx.doi.org/10.1007/s00417-011-1784-8

 
 
Top